Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients
Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent health risks. CEO Dave Ricks emphasizes responsible use amid supply concerns.
How long can Eli Lilly ride the weight-loss drug boom?
The company is set to become the first $1tn drugmaker, but investors see warning signs it has reached ‘peak enthusiasm’
BioAge valued at $758 million in debut as investors bet on weight-loss drug frenzy
By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
Weight-loss drug developer BioAge raises $198 million in U.S. IPO
BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the range at $18 per share, the weight-loss drug developer said on Wednesday. The surging popularity of weight-loss drugs,
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.
Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO
Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.
1d
Eli Lilly considers testing weight-loss drugs on people who are not overweight
Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight ...
21h
on MSN
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
In a groundbreaking move, Eli Lilly (NYSE:LLY) is set to test its weight-loss medications on individuals who are not ...
10d
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.
3d
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and ...
1d
Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...
Hosted on MSN
6d
Is Eli Lilly Stock Still a Buy Near All-Time Highs?
Eli Lilly (LLY) stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in ...
13d
Eli Lilly urges court to toss $183 mln Medicaid fraud judgment
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
1d
Eli Lilly & Co: Strong Buy Rating Amid Robust Product Growth and Promising Pipeline
Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target ...
10d
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
13d
Prediction: This Will be Eli Lilly's Next Big Move.
This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...
1d
Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points
ELI LILLY Inc. LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Japan
Kisunla
Food and Drug Administration
Donanemab
Novo Nordisk
Feedback